Disease relevance of Buccalsone

• The Children's Cancer Group (CCG) 1952 clinical trial for children with standard-risk acute lymphoblastic leukemia (SR-ALL) compared intrathecal (IT) methotrexate (MTX) with IT triples (ITT) (MTX, cytarabine, and hydrocortisone sodium succinate [HSS]) as presymptomatic central nervous system (CNS) treatment [1].
• Bronchospasm caused by intravenous hydrocortisone sodium succinate (Solu-Cortef) in aspirin-sensitive asthmatics [2].
• Curative rate in the patients who received large-dose administration of Solu-cortef was 96.2% in the 24th week, and the therapy was considered to be applicable in routine clinical practice for Bell's palsy [3].

High impact information on Buccalsone

• Other medicines recently available from pharmacies without prescription are the antacid Mucaine, and Adcortyl in Orabase and Corlan pellets for gum and mouth lesions [4].
• In vitro inhibition of endotoxin induced platelet aggregation with hydrocortisone sodium succinate (Solu-Cortef) [5].

Chemical compound and disease context of Buccalsone

• Eleven patients with intrinsic asthma and aspirin sensitivity were challenged with intravenous hydrocortisone sodium succinate (Solu-Cortef; the Upjohn Co., Kalamazoo, Mich.). Three patients showed definite evidence of bronchospasm, which was easily reversed by subcutaneous administration of epinephrine [2].

Biological context of Buccalsone

• Solu-Cortef added to platelet rich plasma during ATP, thrombin, collagen and endotoxin stimulated platelet aggregation resulted in a reversal of the optical density suggesting deaggregation [5].

References